Rasnik Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rasnik Singh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alexa Truong
Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California, USA
1 shared publication - Audrey Bui
Department of Biology, St. Bonaventure University, St. Bonaventure, New York, USA
1 shared publication Benjamin Farahnik
University of Vermont College of Medicine, Burlington, Vermont
1 shared publication- Di Yan
Department of Pathology University of Wisconsin Madison Wisconsin USA
1 shared publication - Hsin-Wen Chang
Department of Dermatology, University of California San Francisco, San Francisco, California, USA
1 shared publication - Jeffrey M. Milush
Department of Medicine, University of California San Francisco, San Francisco, California, USA
1 shared publication
Latest Publications
- Open Access
- 10 March 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (3) , 100115
Multiomic Analysis of the Gut Microbiome in Psoriasis Reveals Distinct Host‒Microbe Associations
- 10 March 2022
- Published by Elsevier in JID Innovations
- Vol. 2 (3) , 100115
Open AccessMultiomic Analysis of the Gut Microbiome in Psoriasis Reveals Distinct Host‒Microbe Associations
- Open Access
- 1 September 2016
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
- Vol. 1 (4) , 161-166
Improvement in Quality of Life in Patients with Moderate to Severe Psoriasis Treated with Adalimumab or Ustekinumab
Introduction: Quality of life (QoL) is an important issue in psoriatic disease that should be included when assessing therapeutic efficacy of treatments. The objective of this study was to compare improvement in the dermatology life quality index (DLQI) between patients treated with adalimumab and ustekinumab. Methods: Analysis was based on two separate open-label 24-week clinical trials assessing DLQI and the Psoriasis Area and Severity Index (PASI) at four-week intervals in adult subjects with moderate to severe psoriasis treated with adalimumab or ustekinumab. Results: There were no statistically significant differences in the improvement in DLQI and PASI between the adalimumab and ustekinumab groups except at week 12 for DLQI and week 8 for PASI (ustekinumab > adalimumab). Discussion: Both adalimumab and ustekinumab improve QoL, but further research is necessary to determine specific factors that improve QoL and if one medication improves QoL more than another.
- 1 September 2016
- Published by SAGE Publications in Journal of Psoriasis and Psoriatic Arthritis®
- Vol. 1 (4) , 161-166
Open AccessImprovement in Quality of Life in Patients with Moderate to Severe Psoriasis Treated with Adalimumab or Ustekinumab
Introduction: Quality of life (QoL) is an important issue in psoriatic disease that should be included when assessing therapeutic efficacy of treatments. The objective of this study was to compare improvement in the dermatology life quality index (DLQI) between patients treated with adalimumab and ustekinumab. Methods: Analysis was based on two separate open-label 24-week clinical trials assessing DLQI and the Psoriasis Area and Severity Index (PASI) at four-week intervals in adult subjects with moderate to severe psoriasis treated with adalimumab or ustekinumab. Results: There were no statistically significant differences in the improvement in DLQI and PASI between the adalimumab and ustekinumab groups except at week 12 for DLQI and week 8 for PASI (ustekinumab > adalimumab). Discussion: Both adalimumab and ustekinumab improve QoL, but further research is necessary to determine specific factors that improve QoL and if one medication improves QoL more than another.